Business Context and Reporting Period
Company: Isis Pharmaceuticals, Inc. (Note: Filing text refers to "Isis Pharmaceuticals, Inc." despite the prompt metadata mentioning "IONIS". The text confirms the registrant name is Isis Pharmaceuticals, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2009
Business Overview: Isis is a biopharmaceutical company focused on antisense technology and microRNA therapeutics. The company operates primarily through two segments: Drug Discovery and Development, and Regulus Therapeutics (a joint venture with Alnylam). In January 2009, the company sold its Ibis Biosciences subsidiary to Abbott Molecular Inc. (AMI), which is now reported as discontinued operations.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2009 | Nine Months Ended Sep 30, 2009 | Nine Months Ended Sep 30, 2008 |
|---|---|---|---|
| Total Revenue | $26.8 million | $89.3 million | $77.5 million |
| Operating Loss | $(10.4) million | $(15.9) million | $(5.0) million |
| Net Income (Loss) from Continuing Ops | $(8.1) million | $(12.6) million | $(5.1) million |
| Net Income (Loss) from Discontinued Ops | $0 | $171.7 million | $(5.9) million |
| Net Income (Loss) Attributable to Isis | $(6.9) million | $162.0 million | $(7.9) million |
| Cash and Cash Equivalents | $149.3 million | $149.3 million (Sep 30, 2009) | $217.9 million (Dec 31, 2008) |
| Short-term Investments | $458.5 million | $458.5 million (Sep 30, 2009) | $273.1 million (Dec 31, 2008) |
| Total Debt & Obligations | Approx. $139.9 million (Sep 30, 2009) |
Liquidity: As of September 30, 2009, the company held $607.8 million in cash, cash equivalents, and short-term investments. Working capital was $504.5 million.
Material Changes vs. Prior Period
- Revenue: Total revenue for the nine months ended September 30, 2009, increased 15% to $89.3 million compared to $77.5 million in the prior year. This increase was driven primarily by revenue from the strategic collaboration with Genzyme. However, revenue for the three-month period decreased slightly to $26.8 million from $29.5 million, largely due to the completion of amortization for an upfront payment from OMJP.
- Operating Expenses: Operating expenses increased significantly to $105.2 million for the nine months ended September 30, 2009, from $82.5 million in the prior year. This 28% increase was attributed to the expansion of clinical development programs (specifically the Phase 3 program for mipomersen), increased costs for Regulus Therapeutics, and expanded drug discovery activities.
- Discontinued Operations: The most significant financial change was the sale of Ibis Biosciences in January 2009. This resulted in a one-time gain of $171.8 million (net of tax) included in discontinued operations for the nine-month period, turning a net loss in the prior year into a substantial net income for the current period.
- Accounting Changes: The company adopted new accounting standards in January 2009 regarding convertible debt and noncontrolling interests. This resulted in the reclassification of the 2 5/8% convertible notes, recording them at a discount and increasing non-cash interest expense.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Clinical Progress: Management reported positive Phase 2 data for ISIS 113715 (diabetes) and successful Phase 1 studies for AIR645 (asthma) and ACHN-490. The company anticipates filing for mipomersen approval in 2010.
- Collaborations: The company continues to rely on partnerships (Genzyme, BMS, OMJP, Alnylam) to fund development. A new collaboration with Alnylam regarding single-stranded RNAi (ssRNAi) technology was amended in April 2009, including an $11 million upfront payment.
- Capital Resources: Management intends to use existing cash and short-term investments to finance operations. However, they may pursue additional financing (equity or debt) if necessary.
Risks and Contingencies:
- Profitability: The company has an accumulated deficit of $689.2 million and expects to incur additional operating losses in the future.
- Regulatory Approval: Success depends on obtaining FDA approval for pipeline drugs. Delays or failures in clinical trials (e.g., mipomersen, ISIS 113715) could materially harm the business.
- Partner Dependence: Revenue is heavily concentrated among a few partners (Partner A accounted for 56% of revenue in the first nine months of 2009). Termination of these partnerships could disrupt funding.
- Intellectual Property: The company faces risks related to patent litigation and the ability to protect its proprietary technology.
- Legal Proceedings: Ongoing litigation with Bruker Daltonics regarding the T5000 System manufacturing agreement.
Investor Verification Checklist
- Discontinued Operations Impact: Verify the sustainability of earnings by excluding the $171.8 million one-time gain from the Ibis sale, which masks the underlying operating loss of $12.6 million from continuing operations.
- Revenue Concentration: Assess the risk associated with Partner A (likely Genzyme) contributing over 50% of total revenue.
- Cash Burn Rate: Monitor the rate of cash consumption given the $105.2 million in operating expenses for the nine-month period and the lack of product sales revenue.
- Convertible Debt: Review the terms of the $162.5 million convertible notes (2 5/8% interest, convertible at $14.63/share) and the impact of the new accounting standard on interest expense.
- Clinical Milestones: Track the progress of the Phase 3 trials for mipomersen and the anticipated 2010 filing date, as these are critical value inflection points.